CAR T-cell therapy (27th August 2019)
Chimeric antigen receptor T-cells (CAR T cells) are T-cells where the DNA has been engineered to produce a modified T-cell receptor for use in immunotherapy. The T-cells are normally captured and activated using polystyrene based magnetic microparticles, which are expensive and can cause issues during T-cell isolation for return to the donor. At Spheritech we are developing a macroporous biopolymer cartridge with immobilised antibodies for T-cell activation. This simplifies the whole process from activation through to T-cell recovery. We hope to launch a range of T-cell activation cartridges in the next 6-8 months.